Andreas Scorilas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8343178/publications.pdf

Version: 2024-02-01

396	13,914	21215 62	58552 86
papers	citations	h-index	g-index

400	400	400	14821
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>Epiâ€miRNAs</scp>: Modern mediators of methylation status in human cancers. Wiley Interdisciplinary Reviews RNA, 2023, 14, e1735.	3.2	5
2	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. Science of the Total Environment, 2022, 804, 150151.	3.9	116
3	Identification and expression analysis of ten novel small non-coding RNAs (sncRNAs) in cancer cells using a high-throughput sequencing approach. Gene, 2022, 809, 146025.	1.0	3
4	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90.	2.9	11
5	A versatile 5â€² RACE-Seq methodology for the accurate identification of the 5â€² termini of mRNAs. BMC Genomics, 2022, 23, 163.	1.2	8
6	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24.	1.7	25
7	Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics. Life, 2022, 12, 30.	1.1	67
8	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine, 2022, 28, 542-554.	3.5	104
9	High Expression of a tRNAPro Derivative Associates with Poor Survival and Independently Predicts Colorectal Cancer Recurrence. Biomedicines, 2022, 10, 1120.	1.4	12
10	Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (PRMT1) Gene, Expressed in Breast Cancer Cells. Genes, 2022, 13, 1133.	1.0	11
11	Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells. Gene, 2021, 768, 145262.	1.0	10
12	Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. Genomics, 2021, 113, 573-581.	1.3	12
13	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. TrAC - Trends in Analytical Chemistry, 2021, 134, 116125.	5.8	88
14	MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 593.	1.7	31
15	Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. International Journal of Molecular Sciences, 2021, 22, 2375.	1.8	17
16	A 3â€² tRNAâ€derived fragment produced by tRNA LeuAAG and tRNA LeuTAG is associated with poor prognosis in Bâ€cell chronic lymphocytic leukemia, independently of classical prognostic factors. European Journal of Haematology, 2021, 106, 821-830.	1.1	11
17	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	2.1	12
18	Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. Clinical Chemistry, 2021, 67, 576-578.	1.5	3

#	Article	IF	Citations
19	The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. Biomedicines, 2021, 9, 333.	1.4	18
20	Nanopore Sequencing Unveils Diverse Transcript Variants of the Epithelial Cell-Specific Transcription Factor Elf-3 in Human Malignancies. Genes, 2021, 12, 839.	1.0	6
21	Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression. Cancers, 2021, 13, 2744.	1.7	42
22	Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes. Pharmacogenomics Journal, 2021, 21, 638-648.	0.9	3
23	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877.	1.7	12
24	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. International Journal of Molecular Sciences, 2021, 22, 8498.	1.8	11
25	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
26	A comprehensive nanopore sequencing methodology deciphers the complete transcriptional landscape of cyclin dependent kinase 4 (CDK4) in human malignancies. FEBS Journal, 2021, , .	2.2	1
27	Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. American Journal of Translational Research (discontinued), 2021, 13, 1594-1606.	0.0	0
28	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. Biomedicines, 2021, 9, 1811.	1.4	8
29	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	1.8	13
30	Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members. International Journal of Molecular Sciences, 2021, 22, 13298.	1.8	2
31	Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. Cancers, 2021, 13, 6064.	1.7	5
32	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis, 2020, 41, 442-451.	1.3	10
33	Identification of novel alternative transcripts of the human Ribonuclease Îº (RNASEK) gene using 3â€² RACE and high-throughput sequencing approaches. Genomics, 2020, 112, 943-951.	1.3	3
34	High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. Clinical Biochemistry, 2020, 75, 62-69.	0.8	23
35	Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma. Molecular Carcinogenesis, 2020, 59, 116-125.	1.3	17
36	Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates, 2020, 48, 100662.	6.5	42

#	Article	IF	Citations
37	Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy. Pediatric Diabetes, 2020, 21, 28-39.	1.2	24
38	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	1.1	31
39	Revised Exon Structure of l-DOPA Decarboxylase (DDC) Reveals Novel Splice Variants Associated with Colorectal Cancer Progression. International Journal of Molecular Sciences, 2020, 21, 8568.	1.8	10
40	Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 8867.	1.8	24
41	Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene using a high-throughput sequencing approach. Genomics, 2020, 112, 4268-4276.	1.3	3
42	A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia. Clinical Biochemistry, 2020, 85, 20-26.	0.8	23
43	The role of circular RNAs in therapy resistance of patients with solid tumors. Personalized Medicine, 2020, 17, 469-490.	0.8	35
44	Contribution of miRNAs, tRNAs and tRFs to Aberrant Signaling and Translation Deregulation in Lung Cancer. Cancers, 2020, 12, 3056.	1.7	7
45	Circular RNAs: A New Piece in the Colorectal Cancer Puzzle. Cancers, 2020, 12, 2464.	1.7	42
46	tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5â€²-tRF-LysCTT Results in Disease Early Progression and Patientsâ€™ Poor Treatment Outcome. Cancers, 2020, 12, 3661.	1.7	31
47	The interplay between miR-1245a and BRCA2 in colorectal cancer. Annals of Translational Medicine, 2020, 8, 1043-1043.	0.7	0
48	Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells. Gene, 2020, 750, 144723.	1.0	4
49	miR â€181a overexpression predicts the poor treatment response and earlyâ€progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573.	2.3	7
50	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. European Journal of Cancer, 2020, 126, 125-135.	1.3	48
51	Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome. Diabetes Research and Clinical Practice, 2020, 164, 108187.	1.1	18
52	Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3â€²RACE and high-throughput sequencing. Gene, 2020, 749, 144708.	1.0	0
53	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 658-667.	0.6	18
54	Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. Leukemia Research, 2019, 87, 106234.	0.4	24

#	Article	IF	Citations
55	The miR-200 family as prognostic markers in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 955-963.	0.8	25
56	Î”Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3075-3087.	1.2	4
57	Circulating exosomal miRNAs: clinical significance in human cancers. Expert Review of Molecular Diagnostics, 2019, 19, 979-995.	1.5	28
58	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates, 2019, 47, 100646.	6.5	81
59	Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing approaches. Gene, 2019, 719, 144075.	1.0	10
60	The lysineâ€specific methyltransferase <scp>KMT</scp> 2C/ <scp>MLL</scp> 3 regulates <scp>DNA</scp> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93
61	THE tRNAâ€DERIVED RNA FRAGMENTS (tRFs) BEARING THE GLYCINE ANTICODONS GCC AND CCC AS EMERGING MOLECULAR BIOMARKERS OF UNFAVORABLE PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Hematological Oncology, 2019, 37, 375-376.	0.8	1
62	HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. PLoS ONE, 2019, 14, e0215984.	1.1	17
63	Novel alternative splice variants of the human protein arginine methyltransferase 1 (PRMT1) gene, discovered using next-generation sequencing. Gene, 2019, 699, 135-144.	1.0	14
64	Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. Carcinogenesis, 2019, 40, 965-974.	1.3	14
65	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. International Journal of Molecular Sciences, 2019, 20, 937.	1.8	8
66	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. International Journal of Molecular Sciences, 2019, 20, 1291.	1.8	47
67	Identification of a novel tRNAâ€derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 498-504.	0.8	28
68	Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. Scientific Reports, 2019, 9, 1512.	1.6	21
69	Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1251-1260.	1.4	9
70	Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology. Genomics, 2019, 111, 642-652.	1.3	18
71	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	0.6	1
72	Natural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents?. Current Medicinal Chemistry, 2019, 26, 5982-6015.	1.2	33

#	Article	IF	Citations
73	Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12. Current Pharmaceutical Biotechnology, 2019, 19, 1064-1075.	0.9	10
74	Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone. Current Pharmaceutical Biotechnology, 2019, 19, 1087-1096.	0.9	10
75	High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, 990-1000.	1.4	28
76	Manfred Schmitt (1947â€“2018). Biological Chemistry, 2018, 399, 923-924.	1.2	0
77	Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. Clinical and Experimental Medicine, 2018, 18, 203-213.	1.9	12
78	Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. Leukemia Research, 2018, 70, 1-7.	0.4	29
79	Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. Annals of Hematology, 2018, 97, 1169-1182.	0.8	17
80	Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer. Analytical and Bioanalytical Chemistry, 2018, 410, 971-980.	1.9	3
81	miRâ€221/222 cluster expression improves clinical stratification of nonâ€muscle invasive bladder cancer (TaT1) patients' risk for shortâ€term relapse and progression. Genes Chromosomes and Cancer, 2018, 57, 150-161.	1.5	26
82	Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status. Clinical Breast Cancer, 2018, 18, 305-312.e3.	1.1	16
83	Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives. Expert Review of Molecular Diagnostics, 2018, 18, 981-991.	1.5	20
84	BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer. Clinical Chemistry and Laboratory Medicine, 2018, 57, 276-287.	1.4	10
85	Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. British Journal of Cancer, 2018, 119, 1477-1486.	2.9	41
86	miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. Expert Review of Molecular Diagnostics, 2018, 18, 963-979.	1.5	41
87	Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing. Gene, 2018, 670, 155-165.	1.0	9
88	Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors. Clinical Biochemistry, 2018, 58, 78-85.	0.8	11
89	A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance. Clinical Biochemistry, 2018, 60, 24-32.	0.8	8
90	Molecular cloning of novel transcripts of the adaptor-related protein complex 2 alpha 1 subunit (AP2A1) gene, using Next-Generation Sequencing. Gene, 2018, 678, 55-64.	1.0	9

#	Article	IF	Citations
91	Expressional profiling and clinical relevance of RNase Î¹ in prostate cancer: a novel indicator of favorable progression-free survival. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2049-2057.	1.2	4
92	BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2104-2118.	1.4	10
93	Novel splice variants of the human kallikrein-related peptidases 11 (KLK11) and 12 (KLK12), unraveled by next-generation sequencing technology. Biological Chemistry, 2018, 399, 1065-1071.	1.2	10
94	Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies. Biological Chemistry, 2018, 399, 821-836.	1.2	10
95	Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. Annals of Translational Medicine, 2018, 6, 243-243.	0.7	10
96	Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Annals of Translational Medicine, 2018, 6, 241-241.	0.7	90
97	Alternative Splicing Detection Toolâ€"a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. Annals of Translational Medicine, 2018, 6, 244-244.	0.7	17
98	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. Molecular Diagnosis and Therapy, 2017, 21, 453-464.	1.6	40
99	Identification and molecular cloning of novel transcripts of the human kallikrein-related peptidase 10 (KLK10) gene using next-generation sequencing. Biochemical and Biophysical Research Communications, 2017, 487, 776-781.	1.0	17
100	mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. Leukemia Research, 2017, 53, 65-73.	0.4	26
101	Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness. Cancer Letters, 2017, 388, 96-106.	3.2	15
102	miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. Clinical Biochemistry, 2017, 50, 918-924.	0.8	25
103	Comparative HPLC-DAD and UHPLC-ESI(-)-HRMS & MS/MS profiling of Hypericum species and correlation with necrotic cell-death activity in human leukemic cells. Phytochemistry Letters, 2017, 20, 481-490.	0.6	11
104	miR-10b is a prognostic marker in clear cell renal cell carcinoma. Journal of Clinical Pathology, 2017, 70, 854-859.	1.0	29
105	Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. Clinical Biochemistry, 2017, 50, 285-292.	0.8	31
106	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2017, 55, 737-747.	1.4	33
107	miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. British Journal of Cancer, 2017, 117, 801-812.	2.9	33
108	The transcriptome of a â€œsleepingâ€•invader: de novo assembly and annotation of the transcriptome of aestivating Cornu aspersum. BMC Genomics, 2017, 18, 491.	1.2	17

#	Article	IF	Citations
109	Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 521-532.	1.2	16
110	MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. Disease Markers, 2017, 2017, 1-10.	0.6	32
111	Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (KLK5 â€“) Tj ETQq1 1 0.784314 rgBT /O	1.6	17
112	Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget, 2017, 8, 6896-6913.	0.8	17
113	Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?. Current Medicinal Chemistry, 2017, 24, 14-56.	1.2	10
114	Pediatric Ependymoma: A Proteomics Perspective. Cancer Genomics and Proteomics, 2017, 14, 127-136.	1.0	8
115	Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of mirâ€200 family members, mirâ€205 and their common targets. Molecular Carcinogenesis, 2016, 55, 1229-1242.	1.3	24
116	High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. Tumor Biology, 2016, 37, 11815-11824.	0.8	44
117	High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis. Clinical Biochemistry, 2016, 49, 890-896.	0.8	32
118	BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. Leukemia and Lymphoma, 2016, 57, 2199-2203.	0.6	9
119	Copper(II) Inverse-[9-Metallacrown-3] Compounds Accommodating ÂNitrato or Diclofenac Ligands: Structure, Magnetism, and Biological Activity. European Journal of Inorganic Chemistry, 2016, 2016, 219-231.	1.0	25
120	Identification of novel alternative splice variants of the BCL2L12 gene in human cancer cells using next-generation sequencing methodology. Cancer Letters, 2016, 373, 119-129.	3.2	26
121	Micro<scp>RNA</scp>â€194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Medicine, 2016, 5, 656-664.	1.3	50
122	Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. Biological Chemistry, 2016, 397, 529-539.	1.2	18
123	Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Expert Opinion on Therapeutic Targets, 2016, 20, 801-818.	1.5	36
124	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clinical Cancer Research, 2016, 22, 1958-1968.	3.2	16
125	mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 315-24.	1.4	15
126	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 704-713.	3.2	173

#	Article	IF	Citations
127	S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. Clinical and Experimental Metastasis, 2016, 33, 63-71.	1.7	14
128	Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget, 2016, 7, 54415-54429.	0.8	41
129	Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes in human osteoarthritis and normal articular cartilage: An investigation into their differential expression. Molecular Medicine Reports, 2015, 12, 4514-4521.	1.1	50
130	Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets?. Gastroenterology Research and Practice, 2015, 2015, 1-18.	0.7	27
131	Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. Clinical and Experimental Metastasis, 2015, 32, 531-541.	1.7	17
132	Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patientsâ€™ poor response to treatment and short-term relapse. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2023-2036.	1.2	10
133	Cisplatin and Paclitaxel Alter the Expression Pattern of miRâ€143/145 and miRâ€183/96/182 Clusters in T24 Bladder Cancer Cells. Clinical and Translational Science, 2015, 8, 668-675.	1.5	10
134	miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. International Journal of Oncology, 2015, 46, 849-859.	1.4	38
135	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2015, 17, 136-144.	1.2	55
136	Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Biomedicine and Pharmacotherapy, 2015, 70, 33-40.	2.5	19
137	Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumor Biology, 2015, 36, 4979-4986.	0.8	17
138	Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2015, 185, 693-703.	1.9	68
139	L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma. Clinical Biochemistry, 2015, 48, 590-595.	0.8	8
140	Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. Human Pathology, 2015, 46, 673-680.	1.1	25
141	Kallikreins as Biomarkers in Human Malignancies. Biomarkers in Disease, 2015, , 135-165.	0.0	2
142	Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. Breast Cancer Research and Treatment, 2015, 152, 323-336.	1.1	17
143	The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. British Journal of Cancer, 2015, 112, 1527-1535.	2.9	48
144	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. Clinical Biochemistry, 2015, 48, 849-854.	0.8	27

#	Article	IF	Citations
145	Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis, 2015, 36, 528-537.	1.3	67
146	Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes. Tumor Biology, 2015, 36, 3197-3207.	0.8	10
147	Prognostic and predictive biomarkers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1567-1576.	1.5	29
148	Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. Gene, 2015, 554, 174-180.	1.0	4
149	Molecular Biomarkers of Laryngeal Cancer Laryngeal squamous cell carcinoma (LSCC) Tumor markers. Biomarkers in Disease, 2015, , 891-919.	0.0	4
150	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	0.8	67
151	Editorial (Thematic Issue: The Effects of Anticancer Agents on Cell Apoptosis and on the Expression of) Tj ETQq1 1 0.784314 rgBT /Ov	0.9	3
152	Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1217-27.	1.4	39
153	A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family. Genome Biology and Evolution, 2014, 6, 1314-1326.	1.1	26
154	Targeting kallikrein-related peptidases in prostate cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 365-383.	1.5	25
155	Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumor Biology, 2014, 35, 4673-4685.	0.8	34
156	Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. Biological Chemistry, 2014, 395, 1105-1117.	1.2	24
157	Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. British Journal of Cancer, 2014, 110, 1250-1259.	2.9	52
158	KLK11 mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. Biomarkers in Medicine, 2014, 8, 671-685.	0.6	30
159	Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biological Chemistry, 2014, 395, 1095-1104.	1.2	29
160	A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Medicine, 2014, 20, 1199-1205.	15.2	160
161	BCL2L12: A promising molecular prognostic biomarker in breast cancer. Clinical Biochemistry, 2014, 47, 257-262.	0.8	18
162	Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma. Biological Chemistry, 2014, 395, 1051-1062.	1.2	14

#	Article	IF	Citations
163	Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Molecular Cancer, 2014, 13, 101.	7.9	141
164	Predictions for the future of kallikrein-related peptidases in molecular diagnostics. Expert Review of Molecular Diagnostics, 2014, 14, 713-722.	1.5	17
165	RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 2933-2946.	3.2	74
166	Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 39.e29-39.e36.	0.8	10
167	Molecular Biomarkers of Laryngeal Cancer. , 2014, , 1-24.		1
168	Nature Promises New Anticancer Agents: Interplay with the Apoptosis-related BCL2 Gene Family. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 375-399.	0.9	33
169	Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 353-374.	0.9	85
170	Kallikreins as Biomarkers in Human Malignancies. , 2014, , 1-25.		1
171	Association of BCL2L12 overexpression with prolonged disease-free survival in breast cancer.. Journal of Clinical Oncology, 2014, 32, e22202-e22202.	0.8	0
172	Quantitative expression analysis of the apoptosisâ€related gene, BCL2L12, in head and neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2013, 42, 154-161.	1.4	25
173	Quantitative expression analysis and prognostic significance of the BCL2-associated Xgene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer, 2013, 13, 293.	1.1	24
174	Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clinical Biochemistry, 2013, 46, 1453-1461.	0.8	48
175	The role of transcription factors in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1563-1571.	1.4	14
176	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 1163-1170.	1.9	66
177	Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumor Biology, 2013, 34, 369-378.	0.8	7
178	Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Letters, 2013, 330, 106-112.	3.2	30
179	l-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patientsâ€™ survival with stomach adenocarcinomas. Journal of Cancer Research and Clinical Oncology, 2013, 139, 297-306.	1.2	8
180	Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. Medical Oncology, 2013, 30, 405.	1.2	16

#	Article	IF	Citations
181	Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer. Clinical Chemistry, 2013, 59, 261-269.	1.5	65
182	The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. International Journal of Oncology, 2013, 42, 1770-1777.	1.4	60
183	The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. British Journal of Cancer, 2013, 108, 2573-2581.	2.9	90
184	QuantifiedKLK15Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. Prostate, 2013, 73, 1191-1201.	1.2	17
185	Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiology and Oncology, 2013, 47, 319-329.	0.6	38
186	Highlight: Kinin 2012 in Paris. Biological Chemistry, 2013, 393, 299-300.	1.2	1
187	Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity ofBCL-2family gene members in stomach cancer cells. Cancer Biology and Therapy, 2013, 14, 587-596.	1.5	24
188	Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. Thrombosis and Haemostasis, 2013, 110, 450-457.	1.8	37
189	Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances. Anti-Cancer Drugs, 2013, 24, 291-299.	0.7	2
190	The kallikreins: old proteases with new clinical potentials. Thrombosis and Haemostasis, 2013, 110, 396-398.	1.8	4
191	Parallel overexpression and clinical significance of kallikrein-related peptidases 7 and 14 (KLK7 &) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	28
192	Evolution of the Plasma and Tissue Kallikreins, and Their Alternative Splicing Isoforms. PLoS ONE, 2013, 8, e68074.	1.1	40
193	Identification of a STAT5 Target Gene, Dpf3, Provides Novel Insights in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e76155.	1.1	13
194	Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Laboratory Investigation, 2012, 92, 46-56.	1.7	48
195	Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biological Chemistry, 2012, 393, 301-317.	1.2	79
196	The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Advances in Hematology, 2012, 2012, 1-15.	0.6	183
197	10 Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine. , 2012, , 201-218.		2
198	Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1877-1891.	1.4	74

#	Article	IF	Citations
199	Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clinical Biochemistry, 2012, 45, 623-630.	0.8	24
200	Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. Clinical Biochemistry, 2012, 45, 1362-1367.	0.8	10
201	Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumor Biology, 2012, 33, 1075-1084.	0.8	21
202	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumor Biology, 2012, 33, 1209-1214.	0.8	14
203	Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors. Tumor Biology, 2012, 33, 1375-1383.	0.8	15
204	The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biology, 2012, 33, 1429-1436.	0.8	22
205	The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumor Biology, 2012, 33, 2069-2078.	0.8	10
206	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathology Research and Practice, 2012, 208, 104-108.	1.0	30
207	Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Human Pathology, 2012, 43, 1037-1043.	1.1	27
208	Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. Gene, 2012, 505, 153-166.	1.0	30
209	L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. BMC Cancer, 2012, 12, 484.	1.1	19
210	l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. Translational Oncology, 2012, 5, 288-296.	1.7	16
211	The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2012, 14, 385-392.	1.2	106
212	DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	3
213	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumor Biology, 2012, 33, 865-875.	0.8	37
214	Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. European Journal of Clinical Investigation, 2012, 42, 777-783.	1.7	7
215	Lâ€dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. BJU International, 2012, 110, E267-73.	1.3	20
216	Kallikreinâ€related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. Journal of Surgical Oncology, 2012, 105, 223-224.	0.8	6

#	Article	IF	Citations
217	Evaluation of the clinical utility of kallikrein-related peptidase 6 gene (KLK6) downregulation in breast cancer.. Journal of Clinical Oncology, 2012, 30, 10606-10606.	0.8	1
218	BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma. Molecular Medicine, 2011, 17, 163-171.	1.9	39
219	Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thrombosis and Haemostasis, 2011, 105, 131-137.	1.8	10
220	BCL2L12 (BCL2-like 12 (proline-rich)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
221	SCAF1 (SR-related CTD-associated factor 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
222	Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. World Journal of Gastroenterology, 2011, 17, 1989.	1.4	25
223	Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 756-763.	1.3	19
224	Clinical evaluation of PRMT1 gene expression in breast cancer. Tumor Biology, 2011, 32, 575-582.	0.8	67
225	Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumor Biology, 2011, 32, 737-744.	0.8	30
226	Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clinical Proteomics, 2011, 8, 5.	1.1	22
227	Kallikreinâ€related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. Prostate, 2011, 71, 1780-1789.	1.2	28
228	Synthesis, spectroscopic study and anticancer activity of a water-soluble Nb(V) peroxo complex. Journal of Inorganic Biochemistry, 2011, 105, 155-163.	1.5	17
229	Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Annals of Oncology, 2011, 22, 877-883.	0.6	36
230	The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. Oncologist, 2011, 16, 1280-1291.	1.9	39
231	Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression. Anticancer Research, 2011, 31, 3093-100.	0.5	9
232	Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumor Biology, 2010, 31, 391-399.	0.8	26
233	Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clinical Biochemistry, 2010, 43, 1205-1211.	0.8	27
234	Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Science, 2010, 101, 693-699.	1.7	18

#	Article	IF	Citations
235	Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. British Journal of Cancer, 2010, 102, 1384-1390.	2.9	50
236	KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biological Chemistry, 2010, 391, 467-74.	1.2	16
237	Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncology, 2010, 6, 269-285.	1.1	55
238	The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma. Journal of Urology, 2010, 183, 743-751.	0.2	149
239	Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochemical and Biophysical Research Communications, 2010, 391, 214-218.	1.0	34
240	Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biological Chemistry, 2010, 391, 505-511.	1.2	75
241	Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thrombosis and Haemostasis, 2009, 101, 373-380.	1.8	19
242	Expression analysis and study of KLK4 in benign and malignant breast tumours. Thrombosis and Haemostasis, 2009, 101, 381-387.	1.8	26
243	The Immunohistochemical Expression of Growth Hormone-Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer. Molecular Medicine, 2009, 15, 242-247.	1.9	7
244	The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. British Journal of Cancer, 2009, 100, 1659-1665.	2.9	55
245	Quantitative Analysis of Human Kallikrein 5 (KLK5) Expression in Prostate Needle Biopsies: An Independent Cancer Biomarker. Clinical Chemistry, 2009, 55, 904-913.	1.5	21
246	Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. Biological Chemistry, 2009, 390, 921-929.	1.2	23
247	Phosphatidylinositol 3â€²-Kinase Catalytic Subunit Î± Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma. Clinical Cancer Research, 2009, 15, 5724-5732.	3.2	99
248	Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. Gynecologic Oncology, 2009, 112, 531-536.	0.6	23
249	Molecular Response of HLâ€60 Cells to Mitotic Inhibitors Vincristine and Taxol Visualized with Apoptosisâ€Related Gene Expressions, Including the New Member BCL2L12. Annals of the New York Academy of Sciences, 2009, 1171, 276-283.	1.8	18
250	Differential Protein Expressions in Renal Cell Carcinoma: New Biomarker Discovery by Mass Spectrometry. Journal of Proteome Research, 2009, 8, 3797-3807.	1.8	78
251	Treatment of Gastric Cancer Cells with 5-Fluorouracil/Leucovorin and Irinotecan Induces Distinct Alterations in the mRNA Expression of the Apoptosis-Related Genes, Including the Novel Gene BCL2L12. Tumor Biology, 2009, 30, 100-107.	0.8	16
252	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thrombosis and Haemostasis, 2009, 101, 741-747.	1.8	37

#	Article	IF	Citations
253	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-546.	1.8	19
254	Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thrombosis and Haemostasis, 2009, 101, 373-80.	1.8	6
255	Expression analysis and study of KLK4 in benign and malignant breast tumours. Thrombosis and Haemostasis, 2009, 101, 381-7.	1.8	10
256	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-6.	1.8	10
257	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thrombosis and Haemostasis, 2009, 101, 741-7.	1.8	21
258	Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clinical Biochemistry, 2008, 41, 1140-1149.	0.8	37
259	The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. Cancer Chemotherapy and Pharmacology, 2008, 61, 703-711.	1.1	31
260	Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. Prostate, 2008, 68, 759-765.	1.2	6
261	Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clinical Biochemistry, 2008, 41, 591-597.	0.8	17
262	Enhanced Concentration-Dependent Cytotoxic Effect of the Dinuclear Copper(II) Complex of<scp>l</scp>-Carnitine [Cu₂(<scp>l</scp>-carnitine)₂Cl₂(H₂O)₂]Cl₂ Compared to<scp>l</scp>-Carnitine or Copper Chloride Dihydrate, in Human Leukemic Cell Lines. Journal of Medicinal Chemistry, 2008, 51, 3713-3719.	2.9	12
263	The PRMT1 gene expression pattern in colon cancer. British Journal of Cancer, 2008, 99, 2094-2099.	2.9	114
264	Prognostic value of kallikreinâ€related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science, 2008, 99, 2224-2229.	1.7	24
265	Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biological Chemistry, 2008, 389, 1427-1434.	1.2	23
266	Molecular Profile of theBCL2Family of the Apoptosis Related Genes in Breast Cancer Cells after Treatment with Cytotoxic/Cytostatic Drugs. Connective Tissue Research, 2008, 49, 261-264.	1.1	34
267	Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Annals of Oncology, 2008, 19, 1271-1277.	0.6	25
268	Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biological Chemistry, 2008, 389, 1467-1475.	1.2	40
269	Trastuzumab plus Paclitaxel or Docetaxel in HER-2â€“Negative/HER-2 ECDâ€“Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer. Oncologist, 2008, 13, 361-369.	1.9	24
270	Effect of bleomycin and cisplatin on the expression profile ofSRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells. Biological Chemistry, 2007, 388, 773-778.	1.2	1

#	Article	IF	Citations
271	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. Clinical Cancer Research, 2007, 13, 6984-6992.	3.2	69
272	Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients. Clinical Cancer Research, 2007, 13, 1742-1748.	3.2	28
273	Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Letters, 2007, 247, 48-55.	3.2	60
274	Enhanced Antileukemic Activity of the Novel Complex 2,5-Dihydroxybenzoate Molybdenum(VI) against 2,5-Dihydroxybenzoate, Polyoxometalate of Mo(VI), and Tetraphenylphosphonium in the Human HL-60 and K562 Leukemic Cell Lines. Journal of Medicinal Chemistry, 2007, 50, 1316-1321.	2.9	26
275	Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2â€²-bipyridine. Journal of Inorganic Biochemistry, 2007, 101, 64-73.	1.5	137
276	Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. British Journal of Cancer, 2007, 96, 362-372.	2.9	43
277	B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecologic Oncology, 2007, 106, 334-341.	0.6	67
278	Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis-Related Genes, Including the New Member, BCL2L12. Annals of the New York Academy of Sciences, 2007, 1095, 35-44.	1.8	38
279	The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemotherapy and Pharmacology, 2007, 61, 251-265.	1.1	50
280	Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Research, 2007, 27, 3651-60.	0.5	28
281	Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biological Chemistry, 2006, 387, 1629-33.	1.2	19
282	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biological Chemistry, 2006, 387, 1081-6.	1.2	34
283	Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochemical and Biophysical Research Communications, 2006, 344, 667-674.	1.0	8
284	10-(2-Biotinyloxyethyl)-9-acridone. Journal of Photochemistry and Photobiology A: Chemistry, 2006, 181, 126-131.	2.0	11
285	Alterations in mRNA Expression of Apoptosis-Related Genes BCL2, BAX, FAS, Caspase-3, and the Novel Member BCL2L12 after Treatment of Human Leukemic Cell Line HL60 with the Antineoplastic Agent Etoposide. Annals of the New York Academy of Sciences, 2006, 1090, 89-97.	1.8	42
286	BCL2Family of Apoptosis-Related Genes: Functions and Clinical Implications in Cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 1-67.	2.7	214
287	Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study. Tumor Biology, 2006, 27, 104-114.	0.8	25
288	Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 1487-1493.	3.2	60

#	Article	IF	Citations
289	Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. Clinical Chemistry, 2006, 52, 1546-1551.	1.5	13
290	Multidisciplinary Therapy of Locally Farâ€Advanced or Inflammatory Breast Cancer with Fixed Perioperative Sequence of Epirubicin, Vinorelbine, and Fluorouracil Chemotherapy, Surgery, and Radiotherapy: Longâ€Term Results. Oncologist, 2006, 11, 563-573.	1.9	9
291	The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biological Chemistry, 2006, 387, 1607-1612.	1.2	29
292	Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols. Clinical Chemistry, 2006, 52, 1879-1886.	1.5	44
293	Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer. Biological Chemistry, 2006, 387, 1613-8.	1.2	6
294	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 2006, 387, 637-41.	1.2	123
295	mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biological Chemistry, 2006, 387, 789-793.	1.2	19
296	Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. Journal of Histochemistry and Cytochemistry, 2006, 54, 905-910.	1.3	70
297	Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. Clinical Chemistry, 2006, 52, 1356-1365.	1.5	5
298	mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete. British Journal of Cancer, 2005, 93, 152-158.	2.9	3
299	Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Oncology Research and Treatment, 2005, 28, 558-564.	0.8	5
300	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Advances in Clinical Chemistry, 2005, 39, 11-79.	1.8	58
301	Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biological Chemistry, 2005, 386, 471-480.	1.2	44
302	Expression of the C-terminal domain of novel human SR-A1 protein: Interaction with the CTD domain of RNA polymerase II. Biochemical and Biophysical Research Communications, 2005, 334, 61-68.	1.0	7
303	Novel biotinylated acridinium derivatives: New reagents for fluorescence immunoassays and proteomics. Clinica Chimica Acta, 2005, 357, 159-167.	0.5	10
304	Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clinica Chimica Acta, 2005, 357, 190-195.	0.5	40
305	Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Clinica Chimica Acta, 2005, 357, 196-201.	0.5	19
306	Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Research, 2005, 25, 3123-33.	0.5	30

#	Article	IF	Citations
307	Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thrombosis and Haemostasis, 2004, 91, 180-186.	1.8	65
308	Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker. Journal of Clinical Oncology, 2004, 22, 678-685.	0.8	73
309	SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression. Biological Chemistry, 2004, 385, 785-90.	1.2	9
310	Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biological Chemistry, 2004, 385, 779-83.	1.2	30
311	mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biological Chemistry, 2004, 385, 1099-103.	1.2	33
312	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clinical Biochemistry, 2004, 37, 230-237.	0.8	43
313	Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clinical Biochemistry, 2004, 37, 823-829.	0.8	47
314	Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer. Journal of Urology, 2004, 171, 187-191.	0.2	117
315	Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Letters, 2004, 205, 97-106.	3.2	68
316	Cisplatin-Induced Apoptosis in HL-60 Human Promyelocytic Leukemia Cells. Annals of the New York Academy of Sciences, 2003, 1010, 153-158.	1.8	43
317	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. Breast Cancer Research and Treatment, 2003, 78, 149-158.	1.1	46
318	Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. International Journal of Cancer, 2003, 106, 605-610.	2.3	56
319	Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clinical Biochemistry, 2003, 36, 135-143.	0.8	68
320	Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate, 2003, 54, 220-229.	1.2	40
321	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate, 2003, 56, 287-292.	1.2	59
322	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, 169, 361-364.	0.2	53
323	Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology, 2003, 61, 1042-1046.	0.5	41
324	Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. Gene, 2003, 310, 79-89.	1.0	22

#	Article	IF	Citations
325	Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. Journal of Clinical Oncology, 2003, 21, 1035-1043.	0.8	188
326	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 346-355.	0.4	62
327	Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer. Journal of Clinical Oncology, 2003, 21, 3119-3126.	0.8	69
328	Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. British Journal of Cancer, 2003, 88, 1101-1104.	2.9	84
329	Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis. Tumor Biology, 2003, 24, 299-309.	0.8	45
330	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 2003, 89, 1081-1088.	1.8	37
331	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, , 361-364.	0.2	2
332	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.4	0
333	The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Research, 2003, 63, 807-11.	0.4	123
334	Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Research, 2003, 63, 2223-7.	0.4	126
335	Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Research, 2003, 63, 2771-4.	0.4	71
336	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 2003, 89, 1081-8.	1.8	16
337	Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Research, 2003, 63, 3958-65.	0.4	109
338	The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Research, 2003, 63, 6543-6.	0.4	42
339	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. British Journal of Cancer, 2002, 87, 1287-1293.	2.9	40
340	Human kallikrein gene 13 (KLK13) expression by quantitative RTâ€“PCR: an independent indicator of favourable prognosis in breast cancer. British Journal of Cancer, 2002, 86, 1457-1464.	2.9	58
341	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. British Journal of Cancer, 2002, 87, 1294-1300.	2.9	42
342	Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. British Journal of Cancer, 2002, 87, 763-771.	2.9	71

#	Article	IF	Citations
343	Polyadenylate Polymerase (PAP) and 3' End pre-mRNA Processing: Function, Assays, and Association with Disease. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 193-224.	2.7	25
344	Determination of Cathepsin B Expression May Offer Additional Prognostic Information for Ovarian Cancer Patients. Biological Chemistry, 2002, 383, 1297-303.	1.2	42
345	Significance of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Human Colorectal Carcinomas. Tumor Biology, 2002, 23, 170-178.	0.8	22
346	Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology, 2002, 60, 714-718.	0.5	49
347	Cloning, physical mapping and structural characterization of the human Î± A -adaptin gene. Gene, 2002, 289, 191-199.	1.0	8
348	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. Clinical Chemistry, 2002, 48, 1241-1250.	1.5	82
349	Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry. Clinical Chemistry, 2002, 48, 1232-1240.	1.5	67
350	Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate, 2002, 51, 126-132.	1.2	64
351	Decreased concentration of human kallikrein 6 in brain extracts of Alzheimerâ€™s disease patients. Clinical Biochemistry, 2002, 35, 225-231.	0.8	49
352	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clinical Chemistry, 2002, 48, 1241-50.	1.5	33
353	Identification and Characterization of a Novel Human Testis-Specific Kinase Substrate Gene Which Is Downregulated in Testicular Tumors. Biochemical and Biophysical Research Communications, 2001, 285, 400-408.	1.0	14
354	Molecular Cloning, Physical Mapping, and Expression Analysis of a Novel Gene, BCL2L12, Encoding a Proline-Rich Protein with a Highly Conserved BH2 Domain of the Bcl-2 Family. Genomics, 2001, 72, 217-221.	1.3	89
355	Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. Clinica Chimica Acta, 2001, 306, 111-118.	0.5	94
356	Expression of Gelatinase-A (MMP-2) in Human Colon Cancer and Normal Colon Mucosa. Tumor Biology, 2001, 22, 383-389.	0.8	46
357	Combined Expression of p53, Bcl-2, and p21WAF-1 Proteins in Lung Cancer and Premalignant Lesions: Association with Clinical Characteristics. Lung, 2001, 179, 265-278.	1.4	18
358	Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. British Journal of Cancer, 2001, 84, 643-650.	2.9	116
359	Codon 89 polymorphism in the human 5 Î± -reductase gene in primary breast cancer. British Journal of Cancer, 2001, 84, 760-767.	2.9	16
360	Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. British Journal of Cancer, 2001, 84, 1488-1496.	2.9	210

#	Article	IF	Citations
361	Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. British Journal of Cancer, 2001, 85, 190-198.	2.9	21
362	Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). Journal of Biological Chemistry, 2001, 276, 53-61.	1.6	103
363	Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 694-699.	1.8	59
364	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1558-1561.	1.8	31
365	The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 2001, 7, 806-11.	3.2	98
366	Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clinical Cancer Research, 2001, 7, 2372-9.	3.2	78
367	Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clinical Cancer Research, 2001, 7, 2380-6.	3.2	95
368	Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Research, 2001, 61, 7811-8.	0.4	72
369	Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. Clinical Biochemistry, 2000, 33, 345-350.	0.8	32
370	TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. Journal of Oral Pathology and Medicine, 2000, 29, 370-375.	1.4	56
371	Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Research and Treatment, 2000, 61, 111-119.	1.1	18
372	Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. Clinical Chemistry, 2000, 46, 859-862.	1.5	27
373	Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen. Journal of Clinical Oncology, 2000, 18, 1036-1036.	0.8	99
374	Streptavidin-Polyvinylamine Conjugates Labeled with a Europium Chelate: Applications in Immunoassay, Immunohistochemistry, and Microarrays. Clinical Chemistry, 2000, 46, 1450-1455.	1.5	69
375	Genomic Organization of the Human Kallikrein Gene Family on Chromosome 19q13.3â€“q13.4. Biochemical and Biophysical Research Communications, 2000, 276, 125-133.	1.0	183
376	Genomic Organization, Physical Mapping, and Expression Analysis of the Human Protein Arginine Methyltransferase 1 Gene. Biochemical and Biophysical Research Communications, 2000, 278, 349-359.	1.0	65
377	Genomic Organization, Mapping, Tissue Expression, and Hormonal Regulation of Trypsin-like Serine Protease (TLSP PRSS20), a New Member of the Human Kallikrein Gene Family. Genomics, 2000, 63, 88-96.	1.3	62
378	The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family â€” genomic characterization, mapping, tissue expression and hormonal regulation. Gene, 2000, 254, 119-128.	1.0	87

#	Article	IF	Citations
379	Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta, 2000, 292, 127-138.	0.5	13
380	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology, 2000, 56, 527-532.	0.5	99
381	DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal of Urology, 2000, 163, 802-805.	0.2	15
382	TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. Cancer Epidemiology Biomarkers and Prevention, 2000, 9, 387-93.	1.1	6
383	Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Research, 2000, 60, 5427-33.	0.4	25
384	Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid. Clinical Chemistry, 1999, 45, 1774-1780.	1.5	34
385	The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA. Clinical Chemistry, 1999, 45, 1960-1966.	1.5	103
386	Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. British Journal of Cancer, 1999, 81, 1385-1391.	2.9	38
387	Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clinical Cancer Research, 1999, 5, 815-21.	3.2	24
388	Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clinical Cancer Research, 1999, 5, 1778-85.	3.2	27
389	The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clinical Chemistry, 1999, 45, 1960-6.	1.5	30
390	Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. Anticancer Research, 1998, 18, 2885-90.	0.5	6
391	Poly(A)polymerase activity levels in breast tumour cytosols. Journal of Experimental and Clinical Cancer Research, 1998, 17, 511-8.	0.4	3
392	Cathepsin D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Research, 1997, 17, 1405-9.	0.5	5
393	Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Research, 1997, 17, 3665-9.	0.5	10
394	c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Research, 1995, 15, 1543-7.	0.5	9
395	Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Research, 1993, 13, 1895-900.	0.5	17
396	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. , 0, .		6